Building a leading microbiome company in oncology

We are a clinical-stage microbiome therapeutics company aiming to
improve survival in cancer.

See News

Corporate profile

We are a clinical-stage microbiome therapeutics company aiming to restore and modulate patient-microbiome symbiosis to improve survival in cancer. To do so, we are developing a novel class of microbiome drug candidates: Microbiome Ecosystem Therapies (MET). MET are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a microbiome ecosystem. Our MET drug development platform leverages gutPrint®, our proprietary AI-based computational biology and our proprietary cGMP manufacturing capacities to deliver innovative new drugs for the treatment of graft-vs-host-disease , the prevention of complications of HSCT for patients with liquid tumors and the improvement of response to immune checkpoint inhibitors in solid tumors. Our team combines expertise ranging from microbiology to data science to oncology and benefits from the commitment of world-leading scientists.

Press Releases

Press Releases

November 13, 2023: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
Press Releases
November 9, 2023: MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results
Press Releases
November 6, 2023: MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT
Press Releases
November 2, 2023: MaaT Pharma Announces Two Poster Presentations for MaaT013 and MaaT033 at the Upcoming ASH Conference
Press Releases
October 31, 2023: MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients’ Responses to Immunotherapies

See more

Media Coverage

Media

October 2, 2023: Interview of Hervé Affagard – La Bourse et La Vie TV (French only)

Media
September 23, 2023: BFM Business interview of Hervé Affagard – Check-up Santé (French only)
Media
September 19, 2023: Le Point – Traitement des cancers : le microbiote intestinal passe en phase industrielle (French only)
Media
September 13, 2023: Endpoints News – MaaT Pharma and CDMO Skyepharma unveil bespoke, and potentially largest, microbiome facility in Europe
Media
July 7, 2023: France 2- Les pouvoirs extraordinaires du corps humain (French only)
Media
April 28, 2023: Microbiome Times – FDA Lifts Hold on Maat Pharma’s Phase 3 Investigational NDA for MaaT013

See more

Posters

Posters

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe

Posters
A Multicentre, Randomized, Double-Blinded, Phase 2b Study Evaluating The Efficacy And Safety Of MaaT033, an Oral, Pooled Microbiome Ecosystem Therapy In Patients Undergoing Allogenic Hematopoietic Cell Transplantation to Improve Overall Survival: the PHOEBUS trial
Posters
Robust Machine Learning (ML) approach for Screening Microbiome Ecosystem Therapies (MET) Drug Candidates in combination with Immune Checkpoint Inhibitors
Posters
Evaluation of a new co-cultured Microbiome Ecosystem Therapy candidate (MaaT03X) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors
Posters
Benchmarking of shotgun metagenomics analysis results obtained with state-of-the-art optimized pipelines on simulated gut microbiome samples
Posters
Restoration of gut microbiota diversity with oral pooled fecal microbiotherapy in acute myeloid leukemia patients after intensive chemotherapy: the phase 1b CIMON trial

Videos

Videos

R&D Day 2022 replay

On June 7th, 2022, MaaT Pharma hosted its virtual R&D Day to share the latest…
Videos
H.C Wainwright Bioconnect 2022 conference replay
Videos
Investors Webcast – 12/13/21 – Corporate Update
Videos
IABS Bioaster – FMT WEBINAR
Videos
EY : Prix de l’Entrepreneur de l’Année
Videos
Hybridays 2021: Savita BERNAL, Chief Business Officer at MaaT Pharma